Pathway AI

Account ⋅ Sign Out

Table of contents

COVID-19-associated pulmonary mucormycosis

Key sources
The following summarized guidelines for the evaluation and management of COVID-19-associated pulmonary mucormycosis are prepared by our editorial team based on guidelines from the Academy of Pulmonary Sciences (APS/FISF 2022).


1.Diagnostic investigations

Diagnostic imaging: obtain CT with IV contrast in the initial evaluation of patients with COVID-19-associated pulmonary mucormycosis.
Show 2 more
Create free account

More topics in this section

  • Laboratory tests

2.Diagnostic procedures

Bronchoscopy: perform early flexible bronchoscopy in most patients with COVID-19-associated pulmonary mucormycosis due to the following advantages:
visualization of airway abnormalities
performing endobronchial biopsies
provision of samples representing the lower respiratory tract (BAL or bronchial washings)

More topics in this section

  • Biopsy

3.Medical management

Antifungal therapy, initial: administer liposomal amphotericin B 5 mg/kg/day as first-line therapy in patients with COVID-19-associated pulmonary mucormycosis. Consider escalating the dose to 10 mg/kg/day in patients with intracranial involvement.
Show 2 more

More topics in this section

  • Antifungal therapy (maintenance)

  • Antifungal therapy (treatment failure)

4.Surgical interventions

Lung resection: perform lung resection in all patients with potentially resectable lung disease.
Show 2 more